| USA TODAY
COVID-19: Pfizer’s vaccine candidate shown to be 90% effective
Pfizer and BioNTech released early study results indicating that their vaccine prevented more than 90% of infections with the virus that causes COVID-19.
U.S. stocks kicked the week off higher Monday on news that a second COVID-19 vaccine candidate showed promise, bolstering hopes of an economic recovery even as new infections surged around the world.
Pharmaceutical company Moderna said its vaccine appears to be 94.5% effective, according to preliminary data. Markets rallied as they did when Pfizer and BioNTech said earlier this month that their potential vaccine had a similar effectiveness rate. Moderna shares jumped 10%.
The Dow Jones industrial average climbed 450 points to as high as 29,942.88, setting a fresh intraday high and putting the blue-chip average on track to eclipse its Feb. 12 record close before the coronavirus pandemic battered the global economy. The S&P 500 added 1.1%, after finishing at a record high on Friday. The Nasdaq Composite rose 0.8%.
Small-company stocks, travel companies such as cruise lines and others that stand to benefit from a re-opening of the economy led the way higher.
‘It’s certainly going to et worse’: Businesses plan more layoffs, hiring freezes as COVID-19 escalates
Having similar results from two different companies is reassuring, said Dr. Stephen Hoge, Moderna’s president.
“Additional positive news on the Covid-19 vaccine front is more evidence that an end to the pandemic is on the horizon and that the economy can eventually reopen without fears of further lockdowns,” David Trainer, chief executive of New Constructs, an investment research firm, said in a note.
While approval for the vaccine can come within weeks, the rollout of the drug will take more time. The U.S. has reported more than 11 million cases and over 246,000 deaths, according to Johns Hopkins University data.
“While this is clearly very good news, the vaccine has not yet been submitted for approval, meaning it will be weeks – or even months – before it is ready to be distributed,” Adam Vettese, analyst at multi-asset investment platform eToro, said in a note.
“Until it is available for widespread use, then I expect markets to remain volatile and to reflect the general nervousness currently felt by investors.”
Even before the vaccine news, markets had been rising as investors welcomed the signing on Sunday of an agreement establishing the world’s biggest trade bloc, a group of 15 countries that includes China, Japan, South Korea, 10 countries in Southeast Asia, New Zealand and Australia. The United States, the No. 1 economy, is not a part of it.
Called the Regional Comprehensive Economic Partnership, the pact mostly will bring already low tariffs lower over a 20-year period. It is expected to have a positive but incremental impact on trade in the region.
Meanwhile, data released Monday showed Japan, the world’s third-largest economy, grew at an upbeat 21% annual pace in the last quarter, the first quarter of growth in nearly a year.
Tokyo’s Nikkei 225 jumped 2.1% and the Hang Seng in Hong Kong picked up 0.9%. The Kospi in South Korea surged 2% and in Australia the S&P/ASX 200 advanced 1.2%. The Shanghai Composite index gained 1.1%.
In Europe, Germany’s DAX climbed 1.3% and the CAC 40 in Paris jumped 2.5%. In Britain, the FTSE 100 advanced 1.8%.
In other trading, benchmark U.S. crude oil gained $1.56 to $41.69 per barrel in electronic trading on the New York Mercantile Exchange. It lost 99 cents to $40.13 on Friday. Brent crude, the international standard, picked up $1.59 to $44.37 per barrel.
The dollar edged up to 104.90 Japanese yen from 104.65 yen. The euro rose to $1.1845 from $1.1836.
Contributing: The Associated Press